#1 Clinical Trials Search in Europe

Sodium S-Lactate Solution

This article explores clinical trials investigating the use of Sodium S-Lactate Solution in peritoneal dialysis for patients with end-stage kidney disease. The trials aim to assess the efficacy and safety of various peritoneal dialysis solutions containing sodium s-lactate, comparing them to standard glucose-based solutions. The studies focus on key outcomes like dialysis adequacy, metabolic parameters, and patient well-being.

Table of Contents

What is Sodium S-Lactate Solution?

Sodium S-Lactate Solution is an important component used in peritoneal dialysis solutions. It is often referred to as a buffer or alkalizing agent in these solutions[1]. Peritoneal dialysis is a treatment used for patients with kidney failure, where the lining of your abdomen (peritoneum) acts as a filter to remove waste products from your blood.

Medical Conditions Treated

The primary medical condition treated with solutions containing Sodium S-Lactate is End-Stage Kidney Disease (ESKD), also known as End-Stage Renal Disease (ESRD)[1]. This is a condition where the kidneys have stopped working well enough for you to survive without dialysis or a kidney transplant.

How It Works

Sodium S-Lactate Solution works as part of a larger peritoneal dialysis solution. Here’s a simple breakdown of how it functions:

  1. The solution is introduced into your abdominal cavity through a catheter.
  2. The Sodium S-Lactate acts as a buffer, helping to maintain the right balance of acids and bases in your body.
  3. As your blood flows through the blood vessels lining your peritoneum, waste products and excess fluid pass from your blood into the dialysis solution.
  4. After a set period, the solution, now containing these waste products, is drained out of your body and replaced with fresh solution.

Composition and Formulation

Sodium S-Lactate Solution is typically part of a more complex peritoneal dialysis solution. These solutions often contain several key components[1]:

  • Sodium S-Lactate Solution: Acts as a buffer
  • Glucose Monohydrate: Helps remove excess fluid from your blood
  • Sodium Chloride: Maintains proper sodium levels
  • Calcium Chloride Dihydrate: Maintains calcium balance
  • Magnesium Chloride Hexahydrate: Maintains magnesium balance

Some formulations may also include Sodium Hydrogen Carbonate as an additional buffer[1].

Administration and Dosage

Peritoneal dialysis solutions containing Sodium S-Lactate are typically administered directly into the peritoneal cavity. The dosage and frequency can vary based on individual patient needs, but generally:

  • Solutions are administered multiple times per day
  • Each exchange (filling and draining the abdomen) can take 30-40 minutes
  • The maximum daily volume is usually around 6 liters[1]

Potential Benefits

The use of Sodium S-Lactate in peritoneal dialysis solutions offers several potential benefits:

  • Helps maintain proper acid-base balance in the body
  • Contributes to the overall effectiveness of peritoneal dialysis in removing waste products
  • May help improve overall quality of life for patients with ESKD
  • Allows for dialysis to be performed at home, offering more flexibility than hemodialysis

Safety and Side Effects

While peritoneal dialysis solutions containing Sodium S-Lactate are generally considered safe, there are some potential side effects and considerations[1]:

  • Peritonitis (infection of the peritoneum) is a serious potential complication
  • Some patients may experience abdominal discomfort or bloating
  • Long-term use may affect the peritoneal membrane
  • Patients with certain conditions (like severe liver disease) may not be suitable candidates for this treatment

Ongoing Research

Research is ongoing to further improve peritoneal dialysis solutions and outcomes for patients. A current study, known as the ELIXIR trial, is evaluating a new glucose-sparing solution called XyloCore[1]. This research aims to:

  • Compare the effectiveness of XyloCore to standard glucose-based peritoneal dialysis solutions
  • Evaluate changes in various health markers, including cholesterol levels, blood sugar control, and fatigue
  • Assess the impact on residual kidney function and overall patient safety

These ongoing studies may lead to improved treatments for patients with end-stage kidney disease in the future.

Aspect Details
Study Type Clinical trial evaluating peritoneal dialysis solutions
Main Objective To demonstrate non-inferiority of new solutions compared to standard glucose-based solutions
Primary Outcome Weekly Kt/V urea (measure of dialysis adequacy)
Secondary Outcomes Cholesterol levels, blood sugar control, hemoglobin, fatigue, ultrafiltration, blood pressure, urine output, residual kidney function
Participant Criteria Adults with ESRD on CAPD for at least 3 months, stable condition
Treatment Duration 6 months
Key Solution Component Sodium S-Lactate Solution
Comparison Standard glucose-based peritoneal dialysis solutions

FAQ

  • What is the main purpose of these clinical trials? The main purpose is to evaluate the efficacy and safety of peritoneal dialysis solutions containing Sodium S-Lactate Solution, compared to standard glucose-based solutions, for patients with end-stage kidney disease.
  • What is the primary outcome measure in these trials? The primary outcome measure is the weekly Kt/V urea, which is a way to measure dialysis adequacy. The trials aim to demonstrate that the new solutions are not inferior to standard treatments in terms of this measure.
  • What are some of the secondary outcomes being studied? Secondary outcomes include changes in cholesterol levels, blood sugar control, hemoglobin levels, patient fatigue, ultrafiltration (fluid removal), blood pressure, urine output, and residual kidney function.
  • Who is eligible to participate in these trials? Eligible participants are adults with end-stage kidney disease who have been on continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months, are in stable clinical condition, and meet specific criteria regarding their current dialysis regimen and health status.
  • How long do the treatment periods last in these trials? The treatment periods in these trials typically last for 6 months, followed by an after-treatment follow-up period.

Ongoing Clinical Trials on Sodium S-Lactate Solution

  • Study on XyloCore and Drug Combination for Patients with End-Stage Kidney Disease Undergoing Peritoneal Dialysis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Italy Spain Sweden

Glossary

  • End-Stage Kidney Disease (ESRD): A condition where the kidneys have permanently lost their ability to function, requiring dialysis or kidney transplantation to sustain life.
  • Peritoneal Dialysis: A type of dialysis that uses the lining of your abdomen (peritoneum) and a dialysis solution to remove waste and excess fluid from your body.
  • Kt/V urea: A measure of dialysis adequacy, where K is the dialyzer clearance, t is the dialysis time, and V is the volume of distribution of urea.
  • Ultrafiltration: The process of removing excess fluid from the blood during dialysis.
  • Glucose-based solutions: Standard dialysis solutions that use glucose as the primary osmotic agent to remove fluid from the body.
  • Sodium S-Lactate Solution: An alternative component in dialysis solutions being studied to potentially improve outcomes compared to standard glucose-based solutions.
  • Residual Kidney Function: The remaining ability of damaged kidneys to perform some of their functions, which can be important for overall health in dialysis patients.
  • Continuous Ambulatory Peritoneal Dialysis (CAPD): A type of peritoneal dialysis that is performed manually, usually four times a day.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months, used to monitor diabetes control.
  • LDL, HDL, and total cholesterol: Different types of lipids (fats) in the blood that are monitored to assess cardiovascular health risks.

References

  1. http://clinicaltrials.eu/trial/study-on-xylocore-and-drug-combination-for-patients-with-end-stage-kidney-disease-undergoing-peritoneal-dialysis/